Abstract
Background: In recent years, peripheral blood stem cell transplantation has replaced autologous bone marrow transplantation to a large extent in patients with hematological malignancies. Optimal timing and adequate harvesting rely upon the precise quantification of mobilized CD34+ cells in blood and apheresis products. The quality assessment of collected stem cells includes viability tests, short-term culture assays and the determination of CD34+ cells by flow cytometry. External quality controls have suggested the urgent need for greater standardization of the enumeration of CD34+ cells. Material and Methods: We evaluated a single-platform assay for CD34+ cell quantification in peripheral blood and leukapheresis samples (n = 22) by using a four-parameter flow-cytometric method (forward and side angle light scatter, CD34 PE, CD45 FITC) including Flow Count fluorospheres for direct quantification. Results: When processing times of 30 and 300 s were compared, the inter-assay coefficients of variation declined significantly from 11% and 12% in peripheral blood and leukapheresis to 4.7% and 5.2% (p = 0.003 and p = 0.016), respectively. The precision analysis of the flow-cytometric method (intra-assay variation) generated coefficients of variation, which dropped from 8.1% and 8.5%, respectively, to 3.3% for both samples with regard to the processing time (p < 0.001). Conclusion: The data demonstrate the need of single-platform flow-cytometric methods based on fluorescent microparticles. They showed a greater precision of CD34+ cell enumeration over the course of analysis time. Because of its clinical relevance in peripheral blood stem transplantation, these improvements should supplement the current guidelines.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.